A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- NaviFUS Corporation
- Target Recruit Count
- 32
- Registration Number
- NCT06496971
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
A Pilot Study to Evaluate the Efficacy and Safety of NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- NaviFUS Corporation
- Target Recruit Count
- 16
- Registration Number
- NCT06492720
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
Phase 1
Not yet recruiting
- Conditions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- NaviFUS Corporation
- Target Recruit Count
- 8
- Registration Number
- NCT06388707
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Stanford University School of Medicine, Palo Alto, California, United States
🇺🇸University of Virginia School of Medicine, Charlottesville, Virginia, United States
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
Phase 1
Not yet recruiting
- Conditions
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- NaviFUS Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT06329570
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- NaviFUS Corporation
- Target Recruit Count
- 12
- Registration Number
- NCT04999046
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- NaviFUS Corporation
- Target Recruit Count
- 8
- Registration Number
- NCT04988750
- Locations
- 🇨🇳
Chang Gung Medical Foundation, Taoyuan, Taiwan
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- NaviFUS Corporation
- Target Recruit Count
- 6
- Registration Number
- NCT04446416
- Locations
- 🇨🇳
Linkou Chang Gung Memorial Hospital, Taoyuan City, Taiwan
Safety of Using NaviFUS System in Patients With Drug Resistant Epilepsy
- First Posted Date
- 2019-03-01
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- NaviFUS Corporation
- Target Recruit Count
- 6
- Registration Number
- NCT03860298
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2019-06-21
- Lead Sponsor
- NaviFUS Corporation
- Target Recruit Count
- 6
- Registration Number
- NCT03626896
- Locations
- 🇨🇳
Linkou Chang Gung Memorial Hospital, Taoyuan City, Taiwan
© Copyright 2024. All Rights Reserved by MedPath